Current advance of polypoidal choroidal vasculopathy in diagnosis and treatment

Authors: Zhou Nan,  Wei Wenbin

DOI: 10.3760/cma.j.issn.2095-0160.2019.01.017
Published 2019-01-10
Cite as Chin J Exp Ophthalmol, 2019,37(1): 77-80.

Abstract

Polypoidal choroidal vasculopathy (PCV) is a kind of fundus disease characterized by choroidal anomalous branch vascular network and terminal polypoidal dilatation.The pathological basis of idiopathic choroidal neovascularization is similar to age-related macular degeneration (AMD). It is controversial that whether PCV and AMD is the same disease.Optical coherence tomography angiography (OCTA) is a new, noninvasive imaging technique that plays an important role in clinical practice.OCTA not only provides B-scans of the retina, but also offers rapid, high-resolution, repeated and accurate visualization of blood flow, which provides representation of the vascular morphology of the retina and choroid.OCTA is a noninvasive imaging modality capable of evaluating and assessing the morphology of PCV and their associated vascular patterns.The vascular endothelial growth factor (VEGF) participates in the pathophysiology of PCV, so anti-VEGF therapy has become the first-line treatment for PCV.Intravitreal injection of bevacizumab, ranibizumab, and aflibercept improves and stabilizes the vision of patients with PCV.In this article, we summarized the new progress of diagnosis and treatment associated with PCV.

Key words:

Polypoidal choroidal vasculopathy; Optical coherence tomography angiography imaging; Clinical feature; Diagnose; Therapy

Contributor Information

Zhou Nan
Beijing Tongren Eye Center, Beijing Ophthalmology Visual Sciences Key Lab, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
Wei Wenbin
(Read 40 times, 1 visits today)
Updated: September 4, 2019 — 6:26 am